Skip to content

Hemodynamic Stability of Dexmedetomidine in Hypertensive Patients Undergoing Laparoscopic Cholecystectomy

To Observe the Hemodynamic Stability of Dexmedetomidine in Hypertensive Patients Undergoing Laparoscopic Cholecystectomy.

Status
UNKNOWN
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04646317
Enrollment
44
Registered
2020-11-27
Start date
2020-12-30
Completion date
2021-03-02
Last updated
2020-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Laparoscopic Cholecystectomy

Keywords

Attenuation, dexmedetomidine, pneumoperitoneum, hemodynamic stability, pressor response, laryngoscopy response, intubation response

Brief summary

Dexmedetomidine provides better hemodynamic stability to the patients with hypertension undergoing laparoscopic cholecystectomy.

Detailed description

Laparoscopic surgeries form an essence of today's surgical practice because of its magnification, less cosmetic scar, less postoperative pain, and decreased hospital stay along with less morbidity and mortality. According to the American Heart Association (AHA), approximately 86 million adults (34%) in the United States are affected by hypertension, which is defined as a systolic blood pressure (SBP) of 140 mm Hg or more or a diastolic blood pressure (DBP) of 90 mm Hg or more, taking anti-hypertensive medication of those with high blood pressure (BP), 78% were aware they were hypertensive, 68% were being treated with anti-hypertensive agents, and only 64% of treated individuals had controlled hypertension. Anaesthetic management in these patients has become complicated due to cardiopulmonary changes occurring during creation of pneumoperitoneum with CO2 and patient position required for different laparoscopy surgeries. Effects of pneumoperitoneum for laparoscopic surgeries on heart rate and blood pressure was recognized more than 50years ago and the magnitude of the changes was observed to depend on the depth of anesthesia. The cardiovascular, neuroendocrine, and renal changes induced by the CO2 pneumoperitoneum produce a complex pathophysiological state remarkably similar to that in patients with chronic heart failure, though the initiating event is clearly very different. In normotensive subjects these hemodynamic changes are short lived5and probably of little significance. However, these haemodynamic alterations are hazardous to the patients with hypertension, myocardial insufficiency or cerebrovascular disease. Various pharmacologic and nonpharmacological methods have been tried to limit the pressor response following the creation of pneumoperitoneum. The success rate is variable with different methods because each method has its own merits and demerits. In several clinical trials drugs like opioids, β-blockers, lidocaine, nitrate calcium channel blockers or magnesium have already been used orally or parenterally to obtund this sympathoadrenal response. Recently, there is considerable interest in the use of α2-adrenergic agonists to provide hemodynamic stability during pneumoperitoneum. Dexmedetomidine famous for its awake sedation is eight times more selective than clonidine for the α2-adrenergic receptors. The ratio of α2:α1 activity of dexmedetomidine is 1620:1. It activates pro-survival kinases and attenuates ischemia and hypoxic injury, including cardio protection. Concurrent infusion during surgery reduces anesthetic consumption by 20-50% , and produces a decrease in heart rate and blood pressure that may be advantageous for hypertensives. Hypertension associated to pneumoperitoneum in normotensive patients has been controlled with the loading dose of dexmedetomidine. So our rational is to see the hemodynamic stability of dexmedatomindine in hypertensive patients undergoing pneumoperitoneum.

Interventions

DRUGDexmedetomidine injection

Infusion of dexmedetomidine will be prepared in Four syringes of 50ml containing dexmedetomidine in concentration of 1 microgram per millilitre.

DRUGNormal Saline

0.9% as placebo

Sponsors

Dr. Ruth K.M. Pfau Civil Hospital, Karachi
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Caregiver)

Masking description

Patients and care provider do not know about the interventions

Intervention model description

Randomised control trial

Eligibility

Sex/Gender
ALL
Age
17 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Hypertensive patients of both genders of age 17 years to 70 years who are undergoing laparoscopic cholecystectomy. * ASA II and III

Exclusion criteria

* Patients with a prior history of cardiac disease like ischemic heart disease, valvular disorders, undergone previous valve replacements, infective endocarditis and rheumatic fever. * Renal diseases like acute kidney injury and chronic renal diseases. * Endocrinal diseases like pheochromocytoma, hyperthyroidism, hypothyroidism, cushing disease etc. * Pregnant and lactating females * Short thick neck with anticipated difficult intubation * Any sort of obstructive restrictive or reactive airway disease * Patient allergic to any of the study medications. * Obese patients (BMI\>35) * Narcotic addicts

Design outcomes

Primary

MeasureTime frameDescription
Change in Systolic blood pressure during pneumoperitoneumFrom baseline to the end of pneumoperitonium, an average of 2 hoursSystolic blood pressure will be noted on baseline, after induction, every 5 minutes after induction to the end of pneumoperitonium and every 5 minutes for 30 minutes post operatively
change in Diastolic blood pressure during pneumoperitoneumfrom baseline to the end of pneumoperitoneum, an average of 2 hoursDiastolic blood pressure will be noted on baseline, after induction, every 5 minutes after induction to the end of pneumoperitonium and every 5 minutes for 30 minutes post operatively
change in Mean Arterial blood pressure during pneumoperitoneumfrom baseline to the end of pneumoperitoneum, an average of 2 hoursMean Arterial blood pressure will be noted on baseline, after induction, every 5 minutes after induction to the end of pneumoperitonium and every 5 minutes for 30 minutes post operatively
change in Heart Rate during pneumoperitoneumfrom baseline to the end of pneumoperitoneum, an average of 2 hoursHeart rate will be noted on baseline, after induction, every 5 minutes after induction to the end of pneumoperitonium and every 5 minutes for 30 minutes post operatively

Secondary

MeasureTime frameDescription
Post operative sedationevery 5 minutes, up to 30minutesModified Ramsey score use for sedation, it consist of 1-6 where 6 indicates worst(no response) and 6 indicates good response From completion of surgery to 30 minutes post operatively
Systolic blood pressure intubationInductionSBP will be noted at the induction.
Complicationevery 5 minutes from induction, up to 30 minutes post procedurebradycardia, tachycardia, hypertension and hypotension
Post operative analgesiaevery 5 minutes, up to 30minutesVisual analogue scale From completion of surgery to 30 minutes post operatively (0 no pain, 10 wost pain)
Diastolic Blood pressure intubationInductionDBP will be noted at the induction
Mean Arterial blood pressure intubationInductionMAP will be noted at the induction.
heart rate intubationInductionHR will be noted at the induction.

Countries

Pakistan

Contacts

Primary ContactMuhammad Imran, FCPS
dr.imranriasat@gmail.com+923342947181
Backup ContactHanya Javaid, FCPS
drhanyajavaidi@gmail.com+923452424442

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026